Recursion Pharmaceuticals Inc.
Clinical trials sponsored by Recursion Pharmaceuticals Inc., explained in plain language.
A clinical-stage biotech using AI to discover and develop drugs.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New drug aims to shrink polyps in inherited colon cancer condition Results expected Jun 2027 (estimated)
-
Can a pill target tumors with the PIK3CA-H1047R mutation?
Disease control Recruiting nowResearchers are testing an experimental oral drug called REC-7735 in adults with advanced solid tumors that carry a specific change in the PIK3CA gene, known as H1047R. The trial enrolls about 90 participants whose cancer cannot be removed by surgery or has spread, and who have a…
Phase 1/2 • Sponsor: Recursion Pharmaceuticals Inc. • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
New daily pill hopes to shrink Hard-to-Treat cancers
Disease control Recruiting nowThis study tests an experimental daily pill called REC-1245 in people with advanced solid tumors or lymphomas that have not responded to or are not eligible for standard therapies. The main goals are to find a safe dose and check if the drug can shrink tumors. About 170 adults wi…
Phase 1/2 • Sponsor: Recursion Pharmaceuticals Inc. • Aim: Disease control
Last updated Aug 22, 2026 00:00 UTC
-
New drug aims to shrink polyps in inherited colon cancer condition
Disease control Recruiting nowThis study tests an experimental drug called REC-4881 in 67 adults with familial adenomatous polyposis (FAP), a genetic condition that causes many polyps in the colon and small intestine. The goal is to see if the drug can safely reduce the number and size of polyps, helping cont…
Phase 1/2 • Sponsor: Recursion Pharmaceuticals Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC